Novavax Raises 2026 View to $275M as Sanofi Collaboration Advances

Higher outlook matters because it extends Novavax's runway

Novavax raised its adjusted revenue framework to $235 million-$275 million and also improved its combined R&D and SG&A expense guidance by $10 million at the midpoint. That is more than a better forecast. It points to more cash available now and a longer runway before financing becomes the central investment question.

Novavax also reported second-quarter revenue of $57 million. On its earnings call, management said it delivered double-digit sales growth and strong business EPS growth. The message is that the business is not relying on a single cash event to drive the story.

Sanofi has also told Novavax it is in advanced discussions with regulators on the timing of its Phase 3 COVID-19/flu combination trial. If that progress leads to milestones, more partnership-driven revenue could arrive sooner rather than later.

The key risk is still timing. If Sanofi milestones happen on schedule, the longer runway can support a better valuation narrative. If they slip, investors will again be waiting longer for the cash inflections the market is watching.

Sanofi progress turns Novavax's technology into measurable milestone checkpoints

The more important shift is not the headline quarter. It is that the Sanofi relationship is turning Novavax's technology into a series of defined milestones with attached payments.

Why the cash profile looks different now

Sanofi has already completed the EU marketing-authorization transfer, which triggered a $25 million milestone payment. That matters because some of the value is converting into cash through concrete handoff events, not just future product sales.

The next clear operational marker is manufacturing technology transfer to Sanofi expected in mid-2027. Novavax says that step would trigger a $75 million milestone payment. If it happens on time, that payment would do more than lift revenue; it would also strengthen the balance sheet and buy more time for the rest of the platform strategy.

That is why the raised 2026 framework of $235 million-$275 million matters. The updated outlook already reflects stronger Matrix-M demand and expected Takeda and Serum Institute royalties and milestones. With Sanofi milestones now more visible, partnership-led revenue looks less like a side note and more like a major driver of the model.

What bulls and bears are watching next

Bulls see defined milestones, partner-funded execution, and a lower need for Novavax to carry the full commercial burden alone. Bears see a company that is still dependent on contract milestones and regulatory timing rather than company-owned sales scale.

For now, that is the cleanest way to frame the debate. The upside case works if Sanofi moves through these handoff points on schedule. If those milestones delay, the valuation story loses some of its force.